Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Lee, D. Lim, H. Cho, M. Seon, Jin-Kyung Kim, Boo-Yong Lee, J. Park (2009)Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity.
Cancer letters, 285 2
Wen-Chang Chang, Ben-Kuen Chen (2005)Transcription factor Sp1 functions as an anchor protein in gene transcription of human 12(S)-lipoxygenase.
Biochemical and biophysical research communications, 338 1
Xu Zhang, S. Gillespie, P. Hersey (2004)Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways.
Molecular cancer therapeutics, 3 2
R. Basha, S. Ingersoll, U. Sankpal, Sarfraz Ahmad, C. Baker, J. Edwards, R. Holloway, Sumanth Kaja, M. Abdelrahim (2011)Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.
Gynecologic oncology, 122 1
Ramy Attia, Lidia Gardner, Engy Mahrous, D. Taxman, L. LeGros, Sarah Rowe, J. Ting, A. Geller, M. Kotb (2008)Selective Targeting of Leukemic Cell Growth in Vivo and in Vitro Using a Gene Silencing Approach to Diminish S-Adenosylmethionine Synthesis*
Journal of Biological Chemistry, 283
Rang Xu, Ping Zhang, Jian Huang, S. Ge, Jian Lu, G. Qian (2007)Sp1 and Sp3 regulate basal transcription of the survivin gene.
Biochemical and biophysical research communications, 356 1
D. Altieri (2006)The case for survivin as a regulator of microtubule dynamics and cell-death decisions.
Current opinion in cell biology, 18 6
Q. Shi, X. Le, J. Abbruzzese, Zhihai Peng, C. Qian, Hong-wei Tang, Q. Xiong, Bailiang Wang, Xiang Li, K. Xie (2001)Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Cancer research, 61 10
M. Kavurma, L. Khachigian (2003)Sp1 Inhibits Proliferation and Induces Apoptosis in Vascular Smooth Muscle Cells by Repressing p21WAF1/Cip1 Transcription and Cyclin D1-Cdk4-p21WAF1/Cip1 Complex Formation*
Journal of Biological Chemistry, 278
M. Garcı́a-Gila, E. LÓPEZ‐MARTIN, A. García-Pardo (2002)Adhesion to fibronectin via α4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo‐1 receptors
Clinical & Experimental Immunology, 127
Yuxin Li, Mingxing Xie, Jian Yang, Dongfang Yang, Ruitang Deng, Y. Wan, B. Yan (2006)The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter
I. Castro, T. Bivona, M. Philips, A. Pellicer (2004)Ras Activation in Jurkat T cells following Low-Grade Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the Golgi Apparatus
Molecular and Cellular Biology, 24
O. Eskerod (1994)Gastrointestinal tolerance studies on tolfenamic acid in humans and animals.
Pharmacology & toxicology, 75 Suppl 2
M. Abdelrahim, C. Baker, J. Abbruzzese, S. Safe (2006)Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Journal of the National Cancer Institute, 98 12
L. Cunningham, R. Aplenc (2007)Pharmacogenetics of acute lymphoblastic leukemia treatment response
Expert Opinion on Pharmacotherapy, 8
M. Mityaev, E. Kopantzev, A. Buzdin, T. Vinogradova, E. Sverdlov (2008)Functional significance of a putative Sp1 transcription factor binding site in the survivin gene promoter
Biochemistry (Moscow), 73
Y. Nakagawa, S. Yamaguchi, M. Hasegawa, T. Nemoto, M. Inoue, Kenshi Suzuki, K. Hirokawa, M. Kitagawa (2004)Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Leukemia research, 28 5
P. Ginkel, D. Sareen, L. Subramanian, Quintisha Walker, Soesiawati Darjatmoko, M. Lindstrom, Amol Kulkarni, D. Albert, A. Polans (2007)Resveratrol Inhibits Tumor Growth of Human Neuroblastoma and Mediates Apoptosis by Directly Targeting Mitochondria
Clinical Cancer Research, 13
M Abdelrahim, CH Baker, JL Abbruzzese, S Safe (2006)Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation
J Natl Cancer Inst, 98
C. Pui, S. Jeha (2007)New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Nature Reviews Drug Discovery, 6
Suying Lu, Michael Archer (2010)Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells
International Journal of Cancer, 126
M. Abdelrahim, R. Smith, R. Burghardt, S. Safe (2004)Role of Sp Proteins in Regulation of Vascular Endothelial Growth Factor Expression and Proliferation of Pancreatic Cancer Cells
Cancer Research, 64
N. Aravindan, Rakhesh Madhusoodhanan, Salahuddin Ahmad, Dan Johnson, T. Herman (2008)Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells.
Cancer biology & therapy, 7 4
A. Mita, M. Mita, S. Nawrocki, F. Giles (2008)Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Clinical Cancer Research, 14
D Grossman, PJ Kim, JS Schechner, DC Altieri (2001)Inhibition of melanoma tumor growth in vivo by survivin targeting
Proc Natl Acad Sci U S A, 98
D. Altieri (2003)Validating survivin as a cancer therapeutic target
Nature Reviews Cancer, 3
M. Pennati, M. Folini, N. Zaffaroni (2007)Targeting survivin in cancer therapy: fulfilled promises and open questions.
Carcinogenesis, 28 6
P. Obexer, J. Hagenbuchner, T. Unterkircher, Nora Sachsenmaier, C. Seifarth, G. Böck, V. Porto, K. Geiger, M. Ausserlechner (2009)Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Molecular biology of the cell, 20 7
S. Safe, M. Abdelrahim (2005)Sp transcription factor family and its role in cancer.
European journal of cancer, 41 16
D. Eslin, U. Sankpal, Chriss Lee, R. Sutphin, P. Maliakal, E. Currier, G. Sholler, Moeez Khan, R. Basha (2013)Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma
Molecular Carcinogenesis, 52
S. Ryu, Sharleen Zhou, A. Ladurner, R. Tjian (1999)The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1
R. Basha, C. Baker, U. Sankpal, Sarfraz Ahmad, S. Safe, J. Abbruzzese, M. Abdelrahim (2011)Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.
Frontiers in bioscience, 3
Lan Yuan, I. Ahn, P. Davis (2007)Inhibition of tyrosine phosphorylation of vascular endothelial growth factor receptors in human umbilical vein endothelial cells: a potent anti-angiogenic lipid-rich extract from shark.
Journal of medicinal food, 10 4
D. Waterhouse, W. Dragowska, K. Gelmon, L. Mayer, M. Bally (2004)Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model
Cancer Biology & Therapy, 3
I. Collins, M. Garrett (2005)Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Current opinion in pharmacology, 5 4
U. Sankpal, M. Abdelrahim, Sarah Connelly, Chriss Lee, R. Madero-Visbal, J. Colon, Joshua Smith, S. Safe, P. Maliakal, R. Basha (2012)Small molecule tolfenamic acid inhibits PC‐3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer
The Prostate, 72
D. Grossman, P. Kim, J. Schechner, D. Altieri (2001)Inhibition of melanoma tumor growth in vivo by survivin targeting.
Proceedings of the National Academy of Sciences of the United States of America, 98 2
A. Troeger, M. Siepermann, G. Escherich, R. Meisel, R. Willers, S. Gudowius, T. Moritz, H. Laws, H. Hanenberg, U. Goebel, G. Janka-Schaub, C. Mahotka, D. Dilloo (2007)Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
Haematologica, 92 8
J. Vara, E. Casado, J. Castro, P. Cejas, C. Belda-Iniesta, M. González-Barón (2004)PI3K/Akt signalling pathway and cancer.
Cancer treatment reviews, 30 2
Caroline Craig, R. Wersto, Min Kim, Ekta Ohri, Zhuangwu Li, D. Katayose, Su Lee, J. Trepel, K. Cowan, P. Seth (1997)A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
J. Kersey (1997)Fifty years of studies of the biology and therapy of childhood leukemia.
Blood, 90 11
N. Aravindan, Rakhesh Madhusoodhanan, Shandar Ahmad, D. Johnson, T. Herman (2008)Curcumin inhibits NFκB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells.
Cancer Biology & Therapy, 7
T. Maclachlan, N. Sang, A. Giordano (1995)Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.
Critical reviews in eukaryotic gene expression, 5 2
D. Kokkinakis, A. Brickner, J. Kirkwood, Xiaoyan Liu, J. Goldwasser, Anastasiya Kastrama, C. Sander, D. Bocangel, S. Chada (2006)Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress
Molecular Cancer Research, 4
M. Kavurma, F. Santiago, E. Bonfoco, L. Khachigian (2001)Sp1 Phosphorylation Regulates Apoptosis via Extracellular FasL-Fas Engagement*
The Journal of Biological Chemistry, 276
(2012)Small molecule tolfenamic acid inhibits PC3 cell proliferation and invasion in vitro , and tumor growth in orthotopic mouse model for
S. Konduri, J. Colon, C. Baker, S. Safe, J. Abbruzzese, A. Abudayyeh, M. Basha, M. Abdelrahim (2009)Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression
Molecular Cancer Therapeutics, 8
Q. Deveraux, John Reed (1999)IAP family proteins--suppressors of apoptosis.
Genes & development, 13 3
Malcolm Smith, N. Seibel, S. Altekruse, L. Ries, Danielle Melbert, M. O'Leary, F. Smith, G. Reaman (2010)Outcomes for children and adolescents with cancer: challenges for the twenty-first century.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
Yuqing Chen, Xiaojing Wang, Wei Li, Hailong Zhang, Cheng-ling Zhao, Yan Li, Zhenhuan Wang, Chang-jie Chen (2011)Sp1 Upregulates Survivin Expression in Adenocarcinoma of Lung Cell Line A549
The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, 294
山本 浩平 (2007)Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia
M. Molinari (2000)Cell cycle checkpoints and their inactivation in human cancer
Cell Proliferation, 33
Sabine Paternot, L. Bockstaele, Xavier Bisteau, Hugues Kooken, K. Coulonval, P. Roger (2010)Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase
Cell Cycle, 9
H. Doolittle, Armand Morel, D. Talbot (2010)Survivin-directed Anticancer Therapies - A Review of Pre-clinical Data and Early-phase Clinical Trials Current Issues Novel Therapies
P. Maliakal, M. Abdelrahim, U. Sankpal, C. Maliakal, C. Baker, S. Safe, Luis Herrera, A. Abudayyeh, Sumanth Kaja, R. Basha (2012)Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats
Investigational New Drugs, 30
A. Jemal, R. Siegel, Jiaquan Xu, Elizabeth Ward (2010)Cancer Statistics, 2010
CA: A Cancer Journal for Clinicians, 60
S. Shankar, S. Mani, Kathleen O’Guin, Ekambar Kandimalla, S. Agrawal, B. Shafit-Zagardo (2001)Survivin inhibition induces human neural tumor cell death through caspase‐independent and ‐dependent pathways
Journal of Neurochemistry, 79
Anjali Shah, M. Coleman (2007)Increasing incidence of childhood leukaemia: a controversy re-examined
British Journal of Cancer, 97
M. Abdelrahim, I. Samudio, R. Smith, R. Burghardt, S. Safe (2002)Small Inhibitory RNA Duplexes for Sp1 mRNA Block Basal and Estrogen-induced Gene Expression and Cell Cycle Progression in MCF-7 Breast Cancer Cells*
The Journal of Biological Chemistry, 277
J. Tyner, Abdusebur Jemal, M. Thayer, B. Druker, B. Druker, B. Chang (2011)Targeting survivin and p53 in pediatric acute lymphoblastic leukemia
MA Doolittle Helen, T Denis (2010)Survivin-directed anticancer therapies?a review of pre-clinical data and early-phase clinical trials
European Oncology, 6
Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug, is known to inhibit human cancer cells and mouse tumor growth in some cancer models; however, its anti-leukemic response has not been evaluated. TA targets specificity protein (Sp) transcription factors that mediate the expression of several genes associated with cancer including survivin, a key member of inhibitor of apoptosis protein family. Our aim was to test the anti-leukemic efficacy of TA in pre-clinical experiments. The anti-leukemic response of TA was determined using Jurkat and Nalm-6 cell lines. Cells were treated with increasing (25/50/75 μM) concentrations of TA, and cell viability was measured at 24, 48, and 72 h post-treatment. TA showed a steady and consistent decrease in cell viability following a clear dose and time dependent response. Apoptosis and cell cycle analysis was performed using flow cytometry. Results showed a significant increase in the apoptotic fraction (annexin V positive) following TA treatment, while cell cycle phase distribution analysis showed G0/G1 arrest. TA-induced apoptosis was further confirmed by examining the activation of caspase 3/7 and the expression of cleaved PARP. TA modulated the expression of critical candidates associated with the early phases of cell cycle and validated its efficacy in causing G0/G1 arrest. The Western blot results revealed that TA significantly decreases Sp1 and survivin expression. These results demonstrate that the anti-leukemic response of TA occurs potentially through targeting Sp1 and inhibiting survivin and suggest the efficacy of TA as a novel therapeutic agent for leukemia.
Targeted Oncology – Springer Journals
Published: Apr 23, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.